BioSpace News Archive

SenesTech, Inc. provides a long term solution within the state of California specifically in response to the recommendation by California Department of Fish and Wildlife: i.e. “CDFW Issues Reminder to Avoid Harmful Poisons.”

Will provide new expertise and capabilities in one of the fastest-growing areas of healthcare, positioning Catalent for accelerated long-term growth

Arrowhead Pharmaceuticals Inc. announced that it has received clearance from the U.S. Food and Drug Administration to proceed with an adaptive Phase 2/3 trial with the potential to serve as a pivotal registrational study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.

The patent application has been filed in eight other jurisdictions, and is under examination in Europe, China, Japan, and the USA.

AdvantEdge Healthcare Solutions (“AdvantEdge”), a national leading healthcare billing, coding, and practice management company, today announced successful third party recertification for HIPAA and HITECH privacy and security requirements by 360 Advanced as well as SOC 1 Type 2 and SOC 2 Type 2 for information security and transparency

Harvard University Professor Michael E. Porter, co-founder and board chairman of ICHOM, will be a keynote speaker at the event.

BisEDT is the active pharmaceutical ingredient of Microbion’s therapeutic formulation MBN-101.

Partnership agreement paves the way for employees to earn degrees debt-free

Highlights the urgent need for physicians with extensive clinical experience to specialize in addiction medicine to improve treatment and fill a gap in care to address the nation’s growing drug overdose crisis.

Chemistree Technology Inc. (CSE: CHM) (US OTCQB: CHMJF) (the “Company” or “Chemistree”), is pleased to announce that its wholly owned U.S. subsidiary, American CHM Investments Inc., has signed a letter of intent (LOI) to partner with Applied Cannabis Sciences of New Jersey (“ACS”), a New Jersey-based medical retail dispensary applicant in the upcoming New Jersey round of Request for Applications (RFA)